A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients

Trial Profile

A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Cobitolimod (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms CONDUCT
  • Sponsors InDex Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2017 Last checked against European Clinical Trials Database record.
    • 21 Jun 2017 According to an InDex Pharmaceuticals media release, the first patient has been enrolled in this trial. Professor Walter Reinisch is Medical Advisor in this study.
    • 26 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top